How to Write an FDA 483 Response

Getting a Form FDA 483 is not the end of an inspection — it is the start of the part you actually control. The observations are the investigator’s account of what they saw; the response is the firm’s chance to show FDA what it’s doing about it, and how well that response reads has a real effect on what happens next, up to and including whether the inspection ultimately classifies as VAI or moves toward a Warning Letter.

In brief

A 483 lists observations, not violations or citations — the firm isn’t required to agree with the wording, but ignoring or minimizing a real finding rarely helps.
FDA has said it generally considers a response received within 15 business days of the close of inspection when deciding what action, if any, is warranted — a deadline worth treating as real even though it isn’t written into regulation.
A response that only promises to “fix” each item reads differently than one that shows root cause, immediate correction, and a dated plan tied into the firm’s existing CAPA system under 21 CFR § 820.100.
Overpromising a completion date you can’t hit does more damage to the firm’s record than an honest, later date you actually meet.

What the response actually needs to do

A useful response works through each observation individually and in the order the 483 lists them, rather than answering the inspection as a whole. For each item, that means stating agreement or disagreement with specifics, not just a reaction; describing the root cause rather than only the symptom the investigator happened to see; stating what was corrected immediately; and laying out the broader corrective action plan with a real, committed date. Replacing a broken gauge is a correction. Explaining why the calibration program let a broken gauge stay in service — and what changed in that program so it doesn’t happen again — is the difference between a response FDA reads as an isolated fix and one it reads as a firm that understands its own system well enough to already be repairing it.

Where the 15-day window actually matters

The 15-business-day window isn’t written into the CFR — it’s FDA’s own stated practice, and district offices generally factor in a response received within it before deciding whether to escalate. Missing the window doesn’t forfeit the chance to respond at all — a later response can still matter — but the sooner one lands, the more of a chance it has to shape the same classification decision that follows every closed inspection. Treat the window as a deadline for a first substantive response, not a deadline for having every corrective action fully implemented; a credible plan with real dates is enough at that stage.

Where people get stuck

Disputing an observation without giving FDA anything to check

If you disagree with an observation, say so specifically and back it with something concrete — the procedure that was actually followed, the record the investigator didn’t see. A disagreement stated as opinion, with nothing attached, reads the same as no response at all.

Writing one response for every observation

Individual items commonly get answered with the same paragraph when a firm reuses language across related findings. Even where two observations share a root cause, the response should trace that connection explicitly instead of leaving the reader to assume it.

Promising a date the firm has no real plan to hit

A corrective action plan with a specific date is far more convincing than a promise to “resolve as soon as possible,” but only if the date is realistic. A missed committed date is worse for the firm’s record than the original observation, because it adds a second, self-inflicted finding about whether the firm’s commitments can be trusted.

The CAPA doesn’t end when the response letter is mailed — it ends when the corrective action is actually implemented and verified, which is a longer and less visible job than the response itself. Reading a 483 correctly the first time makes the response easier to write; writing the response well is what gives the rest of the corrective action plan somewhere credible to stand.

Sources & further reading

21 CFR § 820.100 — Corrective and Preventive Action ecfr.gov
FDA — Inspections, Compliance, Enforcement, and Criminal Investigations fda.gov
Regulatory Academy — How to Read a Form FDA 483 regulatoryacademy.com
Regulatory Academy — How to Read an FDA Inspection Classification regulatoryacademy.com

This essay is provided for general educational purposes and reflects the regulatory landscape as of its publication date. It is not legal, regulatory, or career advice.